Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-08-22Clinical Trial Update: Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies [Phase 4]
Phase 4 trial comparing ciprofloxacin to ceftazidime as empirical therapy for high-risk febrile neutropenia in children with hematologic can…
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy [Phase 3]
Phase 3 study evaluating maintenance therapy with venetoclax and azacitidine in adults with acute myeloid leukemia in first remission after …
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: MRD-positive AML Clinical Study [NA]
A China-based clinical trial is recruiting adults with MRD-positive acute myeloid leukemia, sponsored by the Institute of Hematology & Blood…
-
CLINICAL_TRIALS trial_result · 2025-08-19Clinical Trial Update: Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell [Phase 1, Phase 2]
A completed Phase 1/2 study from Stanford evaluated a haploidentical hematopoietic cell transplantation approach using a T-cell depleted gra…
-
CLINICAL_TRIALS trial_result · 2025-08-14Clinical Trial Update: A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia [Phase 3]
A Phase 3 study is evaluating HMPL-306 in IDH1- or IDH2-mutated acute myeloid leukemia and is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-08-12Clinical Trial Update: Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China [Phase 4]
A Phase 4 clinical trial update on oral venetoclax plus subcutaneous azacitidine in newly diagnosed AML patients in China ineligible for int…
-
CLINICAL_TRIALS trial_result · 2025-08-07Clinical Trial Update: Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]
This update concerns a Phase 1 study of UCART123v1.2 in relapsed/refractory acute myeloid leukemia, with the trial listed as active but not …
-
CLINICAL_TRIALS trial_result · 2025-08-06Clinical Trial Update: HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide [Phase 2]
Phase 2 clinical trial evaluating HLA-mismatched unrelated donor bone marrow transplantation with post-transplant cyclophosphamide; the stud…
-
CLINICAL_TRIALS trial_result · 2025-08-06Clinical Trial Update: Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia [EARLY_Phase 1]
An early-phase 1 study evaluated escalating intravenous doses of INA03 as a single agent in adults with relapsed or refractory acute leukemi…
-
CLINICAL_TRIALS trial_result · 2025-08-06Clinical Trial Update: Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) [Phase 1]
Phase 1 trial evaluating venetoclax plus azacitidine followed by donor lymphocyte infusion for very high-risk acute myeloid leukemia in pati…
-
CLINICAL_TRIALS trial_result · 2025-07-29Clinical Trial Update: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant [Phase 1, Phase 2]
Phase 1/2 trial of VCAR33, a donor-derived anti-CD33 CAR T-cell therapy, in relapsed or refractory acute myeloid leukemia after allogeneic h…
-
CLINICAL_TRIALS trial_result · 2025-07-29Clinical Trial Update: A Long-term Follow-up Study of Patients Who Received VOR33
This update provides long-term follow-up information for patients treated with VOR33, but the study has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-07-29Clinical Trial Update: Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML [Phase 2]
A Phase 2 clinical trial is evaluating VAH as a bridging regimen to allogeneic hematopoietic cell transplantation in relapsed/refractory acu…
-
CLINICAL_TRIALS trial_result · 2025-07-29Clinical Trial Update: Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating an allogeneic engineered hematopoietic stem cell transplant lacking CD33, with post-transplant Mylotarg,…
-
CLINICAL_TRIALS trial_result · 2025-07-29Clinical Trial Update: 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome [Phase 1]
Phase 1 clinical trial evaluating 225Ac-DOTA-Anti-CD38 (daratumumab radiolabeled with Actinium-225) in combination with fludarabine, melphal…
-
CLINICAL_TRIALS trial_result · 2025-07-24Clinical Trial Update: Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) [Phase 1]
Phase 1 trial update evaluating haploidentical donor natural killer cell infusion with IL-15 in patients with acute myeloid leukemia and mye…
-
CLINICAL_TRIALS trial_result · 2025-07-23Clinical Trial Update: First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]
First-in-human Phase 1 dose-escalation study of AFM28 in relapsed/refractory acute myeloid leukemia; the trial status is TERMINATED.
-
CLINICAL_TRIALS trial_result · 2025-07-20Clinical Trial Update: Haplo Peripheral Blood Sct In GVHD Prevention [Phase 1]
Phase 1 trial update reporting the completion of a haploidentical peripheral blood stem cell transplantation approach for the prevention of …
-
CLINICAL_TRIALS trial_result · 2025-07-18Clinical Trial Update: Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML [Phase 2]
Phase 2 trial update evaluating total marrow and lymphoid irradiation plus chemotherapy before donor stem cell transplantation in high-risk …
-
CLINICAL_TRIALS trial_result · 2025-07-15Clinical Trial Update: A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients [Phase 2]
A Phase 2 clinical trial evaluating VA-CAG as induction therapy for newly diagnosed acute myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2025-07-15Clinical Trial Update: CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS [Phase 2]
Phase 2 trial status update for CPX-351 in older patients with refractory or relapsed acute myeloid leukemia and myelodysplastic syndromes; …
-
CLINICAL_TRIALS trial_result · 2025-07-11Clinical Trial Update: Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]
Phase 1 study of KITE-222 in relapsed/refractory acute myeloid leukemia has been terminated with trial results posted.
-
CLINICAL_TRIALS trial_result · 2025-07-09Clinical Trial Update: AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
Phase 1 first-in-human study of AMG 176 in relapsed or refractory multiple myeloma and acute myeloid leukemia was terminated with results po…
-
CLINICAL_TRIALS trial_result · 2025-07-09Clinical Trial Update: Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]
A Phase I/II clinical trial evaluating a proteasome inhibitor in combination with CPX-351 for newly diagnosed TP53-mutated acute myeloid leu…
-
CLINICAL_TRIALS trial_result · 2025-07-08Clinical Trial Update: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96
A completed Italian observational study evaluating real-world outcomes of unfit acute myeloid leukemia patients treated with venetoclax in c…